ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Intervention"

  • Abstract Number: 0426 • ACR Convergence 2024

    Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center

    Caroline Siegel1, Avi Mikhaylov1, Emily Wu2, Deanna Jannat-Khah1, Erika Abramson3, Lisa Sammaritano4 and Nancy Pan5, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Rochester, NY, 3Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Scarsdale, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Rheumatology patients prescribed teratogenic medications often are not prescribed effective contraception. Efforts to improve this important quality indicator are limited by inadequate and poorly…
  • Abstract Number: 0672 • ACR Convergence 2024

    Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE

    Ivanna Romankevych1, Nora Singer2, Kaliyani Marathe3, Angela Merritt1, Ekemini Ogbu4, Chen Chen5, Megan Quinlan-Waters1, Kathleen Pelletier6, Haihong Shi6, Xiaoxing Wang6, Bin Huang7 and hermine brunner4, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, 3Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, DC, 4Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, Cin, OH, 6Pfizer Inc, Groton, CT, 7Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH

    Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…
  • Abstract Number: 1053 • ACR Convergence 2024

    Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases

    Kai Sun1, Lisa Carnago2, Isaac Smith3, Brian Andonian1, Stephen Balevic1, Ankoor Shah1, Catherine Sims4, Kathryn Pollak5, Amy Corneli5, Hayde Bosworth5 and Megan Clowse6, 1Duke University, Durham, NC, 2Duke Health, Hillsborough, NC, 3Duke University Hospital, Durham, NC, 4Duke University, Knightdale, NC, 5Duke University, Durham, 6Duke University, Chapel Hill, NC

    Background/Purpose: Medication nonadherence is as high as 75% among patients with rheumatic diseases, leading to increased morbidity, mortality, and cost. Existing adherence interventions tend to…
  • Abstract Number: 1058 • ACR Convergence 2024

    Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project

    Adrienne Ramirez1, Lisa Walker-Vischer2 and Tzielan Lee3, 1Stanford Medicine - Children's Health, Palo Alto, CA, 2San Jose State University, Campbell, CA, 3Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…
  • Abstract Number: 1063 • ACR Convergence 2024

    AI –Driven Precision in Rheumatologic Emergencies: Unveiling the Capability of Top Healthcare Chatbots

    Abi Fadairo-Azinge1, Jinoos Yazdany2 and Matt Sakumoto3, 1University of California San Francisco UCSF, SAN-FRANCISCO, CA, 2University of California San Francisco, San Francisco, CA, 3Sutter Health Virtual-First Primary Care Physician & CMIO Sutter West Bay Region Sutter Health,Assistant Clinical Professor,Department of Medicine, UCSF, SAN-FRANCISCO, CA

    Background/Purpose: Rheumatologic emergencies are severe, with mortality rates up to 50% even with timely intervention. Associated morbidity includes permanent organ failure and significant disability. This…
  • Abstract Number: 1065 • ACR Convergence 2024

    A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications

    Marta Bean1, Brian Coburn1, Thomas Riley2, Elise Breed1, Carlos M García-González1, Akash Gupta1, Jonathan Kotzin1, Adam Mayer3, John Oghene1, Ellen Romich4, Michael George1, Rachel Dayno1, Nora Sandorfi1, Preethi Thomas1 and Anupama Shahane1, 1University of Pennsylvania, Philadelphia, PA, 2Hopsital of the University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 4University of Pennsylvania, Media, PA

    Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…
  • Abstract Number: 1179 • ACR Convergence 2024

    Development of an Optimal Physiotherapy Intervention to Reduce Stiffness Following Knee Joint Replacement

    Michelle Hall1, Fiona Moffatt1, Ben Smith2, Melanie Narayanasamy3, Joanne Stocks1, Katie Sheehan4 and Catherine Sackley3, 1University of Nottingham, Nottingham, United Kingdom, 2University Hospitals of Derby and Burton NHS Foundation Trust, Derby, England, United Kingdom, 3University of Nottingham, Nottingham, England, United Kingdom, 4Queen Mary University of London, London, England, United Kingdom

    Background/Purpose: Arthrofibrosis is a complication following knee joint replacement due to excessive scar tissue formation. It leads to knee stiffness,  restricted range of movement (ROM)…
  • Abstract Number: 1186 • ACR Convergence 2024

    Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter?

    Neenu Sukumaran1 and John Waterman2, 1University of Connecticut, Avon, CT, 2Veterans Administration, Simsbury, CT

    Background/Purpose: Intra-articular(IA) corticosteroid injections for knee osteoarthritis (OA) have been performed for over 60 years. However, the appropriate dose of IA corticosteroids has not been determined. To…
  • Abstract Number: 1299 • ACR Convergence 2024

    Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development

    Merve Aksoy*, Shadi Jafari-Esfahani*, Yasaman Ahmadzadeh and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI

    Background/Purpose: During their training, internal medicine (IM) residents often have limited exposure to rheumatology, resulting in decreased confidence levels and inadequate scores on the In-training…
  • Abstract Number: 1666 • ACR Convergence 2024

    Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement

    Scott Jamieson1, Jessica Unick2, Kailyn Horn1, Halle Prine1, Chih-Hsiang Yang1 and Christine Pellegrini1, 1University of South Carolina, Columbia, SC, 2Brown Alpert Medical School at Brown University, Providence, RI

    Background/Purpose: After knee replacement (KR), most adults fail to meet recommended levels of physical activity. Virtual options to promote physical activity in clinical populations have…
  • Abstract Number: 1696 • ACR Convergence 2024

    Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide with Sequential Azathioprine for Active Takayasu’s Arteritis: An Open-Label, Randomized-Controlled Trial

    XIAOCHUAN SUN1, Jing Li1, Xinwang Duan2, Liyun Zhang3, Dongyun Yao4, Jing Xue5, zhenbiao wu6, Yi Zhao7, Lijun Wu8, HONGFENG ZHANG9, MENGTAO LI1, Xiaofeng Zeng10, Peter Merkel11 and Xinping Tian12, 1Peking Union Medical College Hospital, Beijing, China, 2The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 3Shanxi Bethune Hosptial, Taiyuan, China (People's Republic), 4Jiaozuo People's Hospital, Jiaozuo, Henan, China (People's Republic), 5Second Affiliated Hospital,Zhejiang University School of Medcine, Hangzhou, China (People's Republic), 6Xijing Hospital, Fourth Military Medical University, Xi'an, China (People's Republic), 7Xuanwu Hospital, Beijing, China, 8People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China (People's Republic), 9The First Affiliated Hospital of Dalian Medical University, Dalian, 10Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, 11University of Pennsylvania, Philadelphia, PA, 12Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: The management of Takayasu’s arteritis (TAK) is challenging for lack of large-scale, high-quality clinical trials. Cyclophosphamide (CYC) is a conventional first-line immunosuppressant but is…
  • Abstract Number: 1940 • ACR Convergence 2024

    Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative

    Bibi Ayesha1, Claudia Castiblanco2, Clement Tagoe3, Sarah Baron2 and Sharon Rikin2, 1Montefiore Medical Center, Metuchen, NJ, 2Montefiore Medical Center, Bronx, NY, 3Montefiore Medical Center, New York

    Background/Purpose:  Uveitis is the inflammation of the eye, which is third leading cause of preventable blindness in the United States. Corticosteroids are the first line…
  • Abstract Number: 2527 • ACR Convergence 2024

    Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)

    Jacques-Eric Gottenberg1, Kathy Sivils2, Kim Campbell3, Jada Idokogi3, Kim Lo3, Sophia G. Liva3, Jonathan Shelton4, Harman Dhatt5, Jonathan J. Hubbard3 and Ghaith Noaiseh6, 1Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 2Johnson & Johnson Innovative Medicine, Edmond, OK, 3Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 4Janssen Scientific Affairs, LLC, San Diego, CA, USA, San Diego, 5Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, USA, Raritan, NJ, 6University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…
  • Abstract Number: 0298 • ACR Convergence 2024

    RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults

    Miwa Haranaka1, Akinori Yamada2, Saki Takahashi2, Keisuke Gotanda2, Sonoko Nakano-Kanatani2, Nana Uemura2, Kensuke Ohnishi2, Masanobu Nishidate2, Ichio Ohnami2 and Megumi Kai3, 1Souseikai Hakata Clinic, Fukuoka, Japan, 2Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 3Oita University, Oita, Japan

    Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
  • Abstract Number: 2572 • ACR Convergence 2024

    Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis

    Remco Erkens1, Gerda Den Engelsman1, Sytze De Roock1, Dörte Hamann1, Dieneke Schonenberg-Meinema2, Merlijn van den Berg2, Mariken Gruppen3, Wineke Armbrust4, Elizabeth Legger5, Sylvia Kamphuis6, Marleen Verkaaik7, Ellen Schatorjé8, Esther Hoppenreijs8, Thomas Vogl9, Johannes Roth9, Petra Hissink Muller10, Joost Swart1, Marc Jansen1, Jorg van Loosdregt11 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Amsterdam University Medical Center, Amsterdam, Netherlands, 3Amsterdam UMC, Amsterdam, Netherlands, 4University Medical Hospital Groningen, Groningen, Netherlands, 5University Medical Center Groningen, Groningen, Netherlands, 6Erasmus University Medical Center, Rotterdam, Netherlands, 7Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, 8University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, 9University of Münster, Münster, Germany, 10Leiden University Medical Center, Leiden, Netherlands, 11University Medical Center Utrecht, La Jolla, CA

    Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology